Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Baxter Advances To Full-Scale Production Of A/H1N1 Vaccine
Baxter International Inc. (NYSE: BAX) announced that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) Collaborating Center] in early May and is diligently working to deliver a pandemic vaccine for use as early as July.
generic viagra online
Three More Sentenced In Fake Drugs Conspiracy Trial, UK
The seventh and final member of a multi-million pound international counterfeit gang was sentenced at Kingston Crown Court earlier this week, 6 July 2009.
News of the day
Prize Winning Research Could Bring Relief To 3.5 Million Denture Stomatitis (Oral Thrush) Sufferers
A research project, which has the potential to bring relief to the estimated 3.5 million UK sufferers of oral thrush, has won the ÷£25,000 Armourers & Brasiers Venture Prize. This will allow the project to proceed to clinical evaluation.
Public Health

AIMSPRO Is Awarded TGA Orphan Status For The Treatment Of Amyotrophic Lateral Sclerosis

Privately owned UK biotech company Daval International Limited has been informed by Australia"s Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig"s disease. AIMSPRO has already achieved TGA Orphan Status for the treatment of Krabbe Leukodystrophy (Krabbe"s disease). Daval is now evaluating an international, multi-centre, placebo controlled, Randomised Clinical Trial to determine whether later stage ALS patients with poor respiratory function can be seen to benefit from the medication under double-blind conditions. AIMSPRO is a new generation biological medicine which is d and manufactured in Australia. It is derived from hyperimmune caprine serum and is currently under Phase II trialling in Europe for advanced Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe by Biotec Distribution (Wales) Limited for clinical trial and "named patient use" purposes. The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in studies addressing critically important indications in standardbred and thoroughbred horses. The Australian regulator, the APVMA, has recently awarded Ceremben a Research Permit, which will enable confirmatory equine field trials to be rapidly completed. Ceremben is also being developed as a potential canine and feline anti-inflammatory agent. Daval International Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009